5-(3,4-dihydroxy-1,5-cyclohexadien-1-yl)-5-phenylhydantoin: metabolite of phenytoin; RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 152954 |
| CHEMBL ID | 3638281 |
| CHEBI ID | 166540 |
| SCHEMBL ID | 14353439 |
| MeSH ID | M0089007 |
| Synonym |
|---|
| CHEBI:166540 |
| 5-(3,4-dihydroxy-1,5-cyclohexadien-1-yl)-5-phenylhydantoin |
| 5-(3,4-dihydroxycyclohexa-1,5-dien-1-yl)-5-phenylimidazolidine-2,4-dione |
| 28129-90-0 |
| 5-dcyph |
| 2,4-imidazolidinedione, 5-(3,4-dihydroxy-1,5-cyclohexadien-1-yl)-5-phenyl- |
| SCHEMBL14353439 |
| 5-(3,4-dihydroxycyclohexa-1,5-dien-1-yl)-5-phenyl-hydantoin |
| CHEMBL3638281 |
| 5-(3,4-dihydroxy-1,5-cyclohexadien-1-yl)-5-phenyl-hydantoin |
| phenytoin dihydrodiol |
| DTXSID20950871 |
| 4-(3,4-dihydroxycyclohexa-1,5-dien-1-yl)-4-phenyl-4h-imidazole-2,5-diol |
| Excerpt | Reference | Relevance |
|---|---|---|
| "We determined PHT bioavailability during steady-state therapy by 1) measurement of the two principal deconjugated PHT urinary metabolites, 5-(4-hydroxyphenyl)-5-phenylhydantoin (p-HPPH) and 5-(3,4-dihydroxy-1,5-cyclohexadien-1-yl)-5-phenylhydantoin (DHD); and 2) direct determination of absolute bioavailability after simultaneous administration of an oral formulation and parenteral stable-labeled PHT (SL-PHT)." | ( Excretion of the principal urinary metabolites of phenytoin and absolute oral bioavailability determined by use of a stable isotope in patients with epilepsy. Aliwarga, T; Brundage, RC; Cloyd, JC; Goel, V; Leppik, IE; Marino, SE; Remmel, RP, 2011) | 0.56 |
| " Absolute bioavailability was 86." | ( Excretion of the principal urinary metabolites of phenytoin and absolute oral bioavailability determined by use of a stable isotope in patients with epilepsy. Aliwarga, T; Brundage, RC; Cloyd, JC; Goel, V; Leppik, IE; Marino, SE; Remmel, RP, 2011) | 0.37 |
| Class | Description |
|---|---|
| imidazolidine-2,4-dione | An imidazolidinone with oxo groups at position 2 and 4. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Pathway | Proteins | Compounds |
|---|---|---|
| Phenytoin (Antiarrhythmic) Action Pathway | 69 | 23 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.38) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||